BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
Glioblastoma and glioma clinical trials and catalysts
Active industry-sponsored trials on ClinicalTrials.gov for glioblastoma: 125 (105 sponsors; 16 newly posted in the last 180 days, 6 stopped in the last 180 days; 10 new-entrant sponsors). Momentum score 9.2, rank 76 of 91 on the disease-area ranking. As of 2026-11-18.
Phase distribution: Early Phase 1 4, Phase 1 36, Phase 2 60, Phase 3 11, Phase 4 2, N/A 12.
Most active sponsors, by phase
| Sponsor | Active trials | By phase | New (window) | Upcoming readouts |
|---|---|---|---|---|
| GT Medical Technologies, Inc. | 3 | NA 1, P3 1, P4 1 | 0 | 0 |
| Telix Pharmaceuticals (Innovations) Pty Limited TLX | 2 | P3 1, P1 1 | 0 | 0 |
| Aivita Biomedical, Inc. | 1 | P3 1 | 0 | 0 |
| Beijing Pearl Biotechnology Limited Liability Company | 1 | P3 1 | 0 | 0 |
| CarThera | 1 | P3 1 | 0 | 0 |
| Everfront Biotech Co., Ltd. | 1 | P3 1 | 0 | 0 |
| Laminar Pharmaceuticals | 1 | P3 1 | 0 | 0 |
| NaviFUS Corporation | 1 | P3 1 | 0 | 1 |
| NovoCure GmbH NVCR | 1 | P3 1 | 0 | 0 |
| Nuvation Bio Inc. NUVB | 1 | P3 1 | 0 | 0 |
| TVAX Biomedical | 1 | P3 1 | 0 | 0 |
| Novartis Pharmaceuticals NVS | 4 | P1 3, P4 1 | 0 | 0 |
| Beijing Biotech | 3 | P1 2, P2 1 | 0 | 3 |
| Alpheus Medical, Inc. | 2 | P1 1, P2 1 | 1 | 0 |
| Beijing Tricision Biotherapeutics Inc | 2 | P2 1, P1 1 | 1 | 0 |
| Black Diamond Therapeutics, Inc. BDTX | 2 | P2 2 | 0 | 0 |
| Boston Scientific Corporation BSX | 2 | NA 1, P1 1 | 1 | 1 |
| BPGbio | 2 | P2 1, NA 1 | 1 | 0 |
| Cerenome CNSY | 2 | P2 1, P1 1 | 0 | 1 |
| ImmunityBio, Inc. IBRX | 2 | P2 2 | 1 | 0 |
| Myosin Therapeutics Inc. | 2 | P2 2 | 1 | 1 |
| Neonc Technologies, Inc. NTHI | 2 | P2 2 | 0 | 2 |
| Novelwise Pharmaceutical Corporation | 2 | P2 2 | 0 | 0 |
| NuvOx LLC NUOX | 2 | P2 1, NA 1 | 0 | 0 |
| Philogen S.p.A. | 2 | P2 2 | 0 | 0 |
Recently stopped trials
- NCT04910022 Nerviano Medical Sciences - terminated: Per the protocol, the sponsor reserves the right to discontinue the trial for valid scientific or administrative reasons. The discontinuatio Ph I/II Study of NMS-03305293+TMZ in Adult Patients With Recurrent Glioblastoma
- NCT06329570 NaviFUS Corporation - suspended: FDA reviewing Safety and Efficacy of Bevacizumab in Combination With NaviFUS System for the Treatment of Recurrent Glioblastoma Multif
- NCT05627323 Chimeric Therapeutics - terminated: IND application withdrawn CAR T Cells in Patients With MMP2+ Recurrent or Progressive Glioblastoma
- NCT03866109 Genenta Science - terminated: LVLP (pt GBM-01034) took place on 27may2026. The 2 remaining slots allocated by the protocol for the additional cohort to generate safety da A Study Evaluating Temferon in Patients With Glioblastoma & Unmethylated MGMT
- NCT05218408 Celularity Incorporated - withdrawn: No participants were enrolled. Study was withdrawn prior to treatment initiation. CYNK-001 IV and IC in Combination With IL2 in Surgical Eligible Recurrent GBM With IDH-1 Wild Type
- NCT03897491 photonamic GmbH & Co. KG - terminated: Low recruitment activities of clinical trial sites. PD L 506 for Stereotactic Interstitial Photodynamic Therapy of Newly Diagnosed Supratentorial IDH Wild-type Glioblastoma
Upcoming trial readouts (next 90 days)
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-11-30 est. | P1/P2 | Neonc Technologies, Inc. NTHI | NCT02704858 Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma | Glioblastoma Multiforme | active not recruiting | 49 |
| 2026-12 est. | P1/P2 | Sapience Therapeutics | NCT04478279 A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors | Glioblastoma; Melanoma Stage IV; Breast Cancer; Prostate Cancer; Glioblastoma Multiforme; GBM; Brain | active not recruiting | 125 |
| 2026-12 est. | P1/P2 | In8bio Inc. INAB | NCT05664243 A Phase 1b / 2 Drug Resistant Immunotherapy With Activated, Gene Modified Allogeneic or Autologous γδ T Cells (DeltEx) in Combination With Maintenance Temozolom | Glioblastoma | active not recruiting | 4 |
| 2026-12-31 est. | P1/P2 | Aveta Biomics, Inc. | NCT06011109 Treatment of Patients With Recurrent High-Grade Glioma With APG-157 and Bevacizumab | Glioma; Glioblastoma Multiforme | active not recruiting | 30 |
| 2026-12-31 est. | P3 | NaviFUS Corporation | NCT06496971 A Prospective Pivotal Study to Evaluate the Efficacy and Safety of Avastin® Bevacizumab (BEV) With or Without Microbubble-mediated Focused Ultrasound (FUS-MB) U | Glioblastoma Multiforme; Glioblastoma; Glioblastoma Multiforme, Adult; Glioma; Brain Tumor; Brain Tu | recruiting | 32 |
| 2026-12-31 est. | P1/P2 | Hangzhou Hanx Biopharmaceuticals, Ltd. | NCT06703255 A Phase 2 Study of HX301 in Patients with High-grade Giloma | Glioma | recruiting | 72 |
| 2027-01 est. | P2 | Imvax | NCT04485949 A Phase 2b Clinical Study With a Combination Immunotherapy in Newly Diagnosed Patients With Glioblastoma | Glioblastoma | active not recruiting | 99 |
| 2027-02 est. | P2 | Eli Lilly and Company LLY | NCT06413706 A Study Comparing Abemaciclib Plus Temozolomide to Temozolomide Monotherapy in Children and Young Adults With High-grade Glioma Following Radiotherapy | Glioma | active not recruiting | 45 |
Readouts in the last 180 days
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-10-31 est. | P1/P2 | Myosin Therapeutics Inc. | NCT07185880 A Phase 1/2 Study of the Safety and Tolerability of MT-125 in GBM Patients | Glioblastoma (GBM) | recruiting | 36 |
| 2026-10-13 est. | P1/P2 | GlaxoSmithKline | NCT06521567 A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer | Melanoma; Hodgkin Lymphoma; High and Low Grade Glioma; Glioblastoma Multiforme (GBM); Diffuse Intrin | active not recruiting | 83 |
| 2026-10 est. | P2 | Sichuan Baili Pharmaceutical Co., Ltd. | NCT06598787 A Study of BL-B01D1 in Patients With Recurrent Glioblastoma | Recurrent Glioblastoma | recruiting | 20 |
| 2026-10 est. | P1/P2 | Philogen S.p.A. | NCT04443010 Safety and Efficacy of L19TNF Plus Temozolomide Chemoradiotherapy in Patients With Newly Diagnosed Glioblastoma | Glioblastoma | recruiting | 226 |
| 2026-10 est. | P1/P2 | Laminar Pharmaceuticals | NCT04299191 Study of LAM561 Acid in Pediatric Patients With Malignant Glioma and Other Advanced Solid Tumors | High-grade Glioma; Solid Tumor, Unspecified, Child | recruiting | 28 |
| 2026-09-30 est. | P2 | Cantex Pharmaceuticals | NCT05986851 Azeliragon in MGMT Unmethylated Glioblastoma | Glioblastoma | active not recruiting | 30 |
| 2026-08-25 est. | P2 | BPGbio | NCT04752813 A Study of BPM31510 With Vitamin K1 in Subjects With Newly Diagnosed Glioblastoma (GB) | Glioblastoma; Glioblastoma Multiforme | active not recruiting | 50 |
| 2026-08-16 est. | P2 | JenKem Technology Co., Ltd. | NCT06595186 JK-1201I Combined with Adjuvant Temozolomide in Patients with Newly Diagnosed Glioblastoma Multiforme (GBM) | Glioblastoma Multiforme (GBM) | recruiting | 25 |
| 2026-06 est. | P2 | Philogen S.p.A. | NCT06336291 A Study With L19TNF in Combination With Lomustine in Patients With Glioblastoma at Progression or Recurrence | Glioblastoma | active not recruiting | 90 |
| 2026-06 est. | P2 | Actuate Therapeutics Inc. ACTU | NCT03678883 9-ING-41 in Patients With Advanced Cancers | Cancer; Pancreatic Cancer; Sarcoma; Renal Cancer; Refractory Cancer; Refractory Neoplasm; Refractory | active not recruiting | 350 |
| 2026-05-27 | P1/P2 | Genenta Science SAEN | NCT03866109 A Study Evaluating Temferon in Patients With Glioblastoma & Unmethylated MGMT | Glioblastoma Multiforme | terminated | 25 |
Landscape counts: ClinicalTrials.gov, industry lead sponsors, active statuses, via the free hosted BioCatalystFeed MCP tool condition_landscape (query "glioblastoma"); readouts matched by condition text. Registry counts only; not a forecast.
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.